Drug treatments for obesity/Bibliography: Difference between revisions

Revision as of 08:41, 9 October 2009

Review Articles

[1] Magni P. et al. (2009) Feeding behavior in mammals including humans. Ann.N.Y.Acad.Sci. 1163:221-232. PMID 19456343

[R2] Coutinho W (2009) The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arquivos Brasileiros De Endocrinologia E Metabologia. 53:262-270 "The most widely used anti-obesity agents are sibutramine and orlistat, both available in clinical practice for about a decade."

[R3] Elangbam C.S (2009) Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns. vet pathol. 26:10-24 "This review covers the current state of antiobesity drugs and their safety concerns, and highlights new therapeutic targets and scientific advances toward the development of appropriate animal models by using novel techniques that will aid in understanding pathogenesis and pathophysiology of anorexigen-related safety issues."

[R4] Bray G (2008) Lifestyle and Pharmacological Approaches to Weight Loss: Efficacy and Safety. J Clin Endocrinol Metab. 93: S81–S88 "There is currently no evidence that clearly supports a superiority of one macronutrient composition for diets used for weight loss...Physical activity is particularly important in helping patients maintain a weight loss once achieved and is less valuable for weight loss itself...but only a few drugs have been developed thattap these mechanisms. Orlistat, which blocks intestinal lipase, is one; sibutramine, a serotoninnorepinephrine reuptake inhibitor, is a second."

Primary Research Papers

[R5] Rossner S, Sjostrom L, Noack R, Meinders A, Noseda G (2000) Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obesity Research.8:41-61 "Orlistat administered for 2 years promotes weight loss and minimizes weight regain. Additionally, orlistat therapy improves lipid profile, blood pressure, and quality of life."

[R6] Hauptman J, Lucas C, Boldrin M, Collins H (2000) Orlistat in the Long-term Treatment of Obesity in Primary Care Settings. Arch Fam Med 9:160–167 "More patients treated with orlistat lost 5% or more of their initial weight in year 1 (48.8% and 50.5% of patients in the 60-mg and 120-mg groups, respectively) compared with placebo (30.7%; P,.001), and approximately 34% of patients in the orlistat groups sustained weight loss of 5% or greater over 2 years compared with 24% in the placebo group (P,.001)."

Books

[R7] Rang H, Dale M, Ritter J, Flower R (2007) Pharmacology. Churchill Livingstone, Elsevier. 417-418.

Websites

[R8] NHS National Institute for Health and Clinical Excellence: Press release (2001), Viewed 7 October 2009, http://www.nice.org.uk/search/guidancesearchresults.jsp?keywords=orlistat&currentpage=2&paginatedpage=1&searchType=All&sort=&pageSize=&startYearMonth=&endYearMonth=&refId=&fromSearch=true

@@ Line 4: / Line 4: @@
 [1] Magni P. ''et al.'' (2009) Feeding behavior in mammals including humans. ''Ann.N.Y.Acad.Sci.'' 1163:221-232. PMID 19456343
-[2] Coutinho W (2009) The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. ''Arquivos Brasileiros De Endocrinologia E Metabologia.'' 53:262-270 ''"The most widely used anti-obesity agents are sibutramine and orlistat, both available in clinical practice for
+[R2] Coutinho W (2009) The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. ''Arquivos Brasileiros De Endocrinologia E Metabologia.'' 53:262-270 ''"The most widely used anti-obesity agents are sibutramine and orlistat, both available in clinical practice for
 about a decade."''
-[3] Elangbam C.S (2009) Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns. ''vet pathol''. 26:10-24 ''"This review covers the current state of antiobesity drugs and their safety concerns, and highlights ''new therapeutic targets and scientific advances toward the development of appropriate animal models by using novel techniques that will aid in understanding pathogenesis and pathophysiology of anorexigen-related safety issues."''
+[R3] Elangbam C.S (2009) Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns. ''vet pathol''. 26:10-24 ''"This review covers the current state of antiobesity drugs and their safety concerns, and highlights ''new therapeutic targets and scientific advances toward the development of appropriate animal models by using novel techniques that will aid in understanding pathogenesis and pathophysiology of anorexigen-related safety issues."''
-[4] Bray G (2008) Lifestyle and Pharmacological Approaches to Weight Loss: Efficacy and Safety. ''J Clin Endocrinol Metab.'' 93: S81–S88 ''"There is currently no evidence that clearly supports a superiority of one macronutrient
+[R4] Bray G (2008) Lifestyle and Pharmacological Approaches to Weight Loss: Efficacy and Safety. ''J Clin Endocrinol Metab.'' 93: S81–S88 ''"There is currently no evidence that clearly supports a superiority of one macronutrient
 composition for diets used for weight loss...Physical activity is particularly important in helping patients
 maintain a weight loss once achieved and is less valuable for weight loss itself...but only a few drugs have been developed thattap these mechanisms. Orlistat, which blocks intestinal lipase, is one; sibutramine, a serotoninnorepinephrine reuptake inhibitor, is a second."''
@@ Line 15: / Line 15: @@
 ==Primary Research Papers==
-[5] Rossner S, Sjostrom L, Noack R, Meinders A, Noseda G (2000) Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. ''Obesity Research''.8:41-61  ''"Orlistat administered for 2 years promotes weight loss and minimizes weight regain. Additionally, orlistat therapy improves lipid profile, blood pressure, and quality of life."''
+[R5] Rossner S, Sjostrom L, Noack R, Meinders A, Noseda G (2000) Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. ''Obesity Research''.8:41-61  ''"Orlistat administered for 2 years promotes weight loss and minimizes weight regain. Additionally, orlistat therapy improves lipid profile, blood pressure, and quality of life."''
-[6] Hauptman J, Lucas C, Boldrin M, Collins H (2000) Orlistat in the Long-term Treatment of Obesity in Primary Care Settings. ''Arch Fam Med'' 9:160–167 ''"More patients treated with orlistat lost 5% or more of their initial weight in year 1 (48.8% and 50.5% of patients in the 60-mg and 120-mg groups, respectively) compared with placebo (30.7%; P,.001), and approximately 34% of patients in the orlistat groups sustained weight loss of 5% or greater over 2 years compared with 24% in the placebo group (P,.001)."''
+[R6] Hauptman J, Lucas C, Boldrin M, Collins H (2000) Orlistat in the Long-term Treatment of Obesity in Primary Care Settings. ''Arch Fam Med'' 9:160–167 ''"More patients treated with orlistat lost 5% or more of their initial weight in year 1 (48.8% and 50.5% of patients in the 60-mg and 120-mg groups, respectively) compared with placebo (30.7%; P,.001), and approximately 34% of patients in the orlistat groups sustained weight loss of 5% or greater over 2 years compared with 24% in the placebo group (P,.001)."''
 ==Books==
-[7] Rang H, Dale M, Ritter J, Flower R (2007) ''Pharmacology''. Churchill Livingstone, Elsevier. 417-418.
+[R7] Rang H, Dale M, Ritter J, Flower R (2007) ''Pharmacology''. Churchill Livingstone, Elsevier. 417-418.
 ==Websites==
-[8] NHS National Institute for Health and Clinical Excellence: Press release (2001), Viewed 7 October 2009, ''http://www.nice.org.uk/search/guidancesearchresults.jsp?keywords=orlistat&currentpage=2&paginatedpage=1&searchType=All&sort=&pageSize=&startYearMonth=&endYearMonth=&refId=&fromSearch=true''
+[R8] NHS National Institute for Health and Clinical Excellence: Press release (2001), Viewed 7 October 2009, ''http://www.nice.org.uk/search/guidancesearchresults.jsp?keywords=orlistat&currentpage=2&paginatedpage=1&searchType=All&sort=&pageSize=&startYearMonth=&endYearMonth=&refId=&fromSearch=true''